摘要
细胞毒性T淋巴细胞相关抗原4(CTLA-4)是一种在T细胞活化过程中起着重要负调控作用从而保持T细胞活化平衡的共刺激分子,近年来研究表明CTLA-4在自身免疫性疾病患者的T细胞及抗原呈递细胞上异常表达,且与疾病的发生发展有着重要关系。由于CTLA-4的特殊作用,围绕它来研究治疗自身免疫性疾病的新途径已成为热点,其中CTLA4-Ig可能在B7-CD28/CTLA-4共刺激通路中抑制B7-CD28途径从而起到治疗自身免疫性疾病的效果,对CTLA-4及共刺激途径的进一步研究在寻找自身免疫性疾病治疗新方法方面有着广阔前景。
Cytotoxic T lymphocyte associated antigen-4（ CTLA-4） is a co-stimulatory molecule which plays a significant negative regulation role in the activation of T cells so as to maintain the balance of T cell activation. Recent studies have indicated that CTLA-4 is unconventionally expressed on T cells and antigen presenting cells in patients with autoimmune diseases,showing great association with the occurrence and development of the diseases. Due to the special function of CTLA-4,a new way to study the treatment of autoimmune diseases around it has become a research hotspot. CTLA4-Ig may have efficacy on treating autoimmune diseases through inhibiting the B7-CD28 pathway in the B7-CD28/CTLA-4 co-stimulatory pathway. Further research on CTLA-4 and the co-stimulatory pathway has broad prospects for finding new ways to treat autoimmune diseases.
作者
胡安印
梁淼
罗舒艳
窦环
HU Anyin;LIANG Miao;LUO Shuyan;DOU Huan(The State Key Laboratory of Pharmaceutical Biotechnology/Medical School of Nanjing University,Nanjing 210093,China)
出处
《医学综述》
2018年第16期3121-3126,3131,共7页
Medical Recapitulate
基金
南京大学本科生创新训练计划国家级项目(G201710284124)
